{
    "sec_cik": "0000203527",
    "sec_company_name": "VARIAN MEDICAL SYSTEMS INC (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20170109",
    "sec_filing_date": "20170110",
    "sec_changed_date": "20170110",
    "sec_accepted_date": "20170110082002",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/203527/000119312517006350/0001193125-17-006350-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/203527/000119312517006350/0001193125-17-006350.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0006\004\VAR_0000203527_EX991_20170109_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "11526 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 7748,
    "endpoints": [
        "EX-99.1   ",
        "Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry or market outlook, including growth drivers; the company’s future orders, revenues, or earnings growth or other financial results; and any statements using the terms “anticipate,” “believe,” “expect,” “plan,” “should,” “will,” “prospects,” “estimated” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to complete the planned distribution on the anticipated timing, or at all; global economic conditions; currency exchange rates and tax rates; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in second-party reimbursement levels; demand for and delays in delivery of the company’s products; the company’s ability to develop, commercialize and deploy new products; the company’s ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; the impact of reduced or limited demand by purchasers of certain X-ray products; challenges associated with commercializing the company’s particle therapy business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company’s reliance on sole or limited-source suppliers; the company’s ability to maintain or increase margins; the impact of competitive products and pricing; the company’s assessment of the goodwill associated with its particle therapy business; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise."
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "VAR",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0006\004\VAR_0000203527_EX991_20170109_EX-99_excerpt.txt",
    "time_elapsed": 0.0,
    "batch_number": 6,
    "batch_signature": "",
    "batch_start_time": "2023-04-16 22:00:52.115412",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-16 22:12:57.751734"
}